Those studies indicated that radiomics analysis was a useful analytical tool to predict HER2 status in breast cancer, which is consistent with the findings of this study.Another radiomic study by Bitencourt et al. [42].developed machine learning models (including both clinical and radiomics MRI features) to predict HER2 expression levels and pathologic response (pCR) after neoadjuvant chemotherapy in HER2 over-expressing breast cancer patients. Here, ERBB2 is linked to breast carcinoma.